M. Arumí

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.

A. Prat, P. Villagrasa, A. Llombart-Cussac, 2019, The Lancet. Oncology.

Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field

E. Zamora, M. Bellet, S. Escrivá-de-Romaní, 2018, Breast Care.

HER2-positive breast cancer: Current and new therapeutic strategies.

C. Saura, M. Bellet, S. Escrivá-de-Romaní, 2018, Breast.

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)

S. Serrano, M. Salido, J. Albanell, 2015, Oncotarget.

Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.

A. Prat, P. Villagrasa, J. Najera-Zuloaga, 2022, European journal of cancer.

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

J. Gavilá, M. Atienza, E. Aguirre, 2023, Clinical and Translational Oncology.

Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).

P. Nuciforo, R. Dienstmann, E. Zamora, 2019, Journal of Clinical Oncology.

HER2-positive breast cancer: Current and new therapeutic strategies.

C. Saura, M. Bellet, S. Escrivá-de-Romaní, 2018, Breast.

Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.

B. González-Farré, D. Sellami, J. M. Ferrero-Cafiero, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.